Teleflex Incorporated — Q3 2023 Form 10-Q
Reporting period: Quarter ended October 1, 2023; comparisons are with the quarter ended September 25, 2022. Year-to-date figures cover nine months. Teleflex develops and sells medical technology products, principally single-use devices used in healthcare settings.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net revenues | $746.4 million | $686.8 million | $2,200.6 million | $2,033.0 million |
| Gross profit | $416.3 million | $374.0 million | $1,215.5 million | $1,109.0 million |
| Gross margin | 55.8% | 54.4% | 55.2% | 54.5% |
| Income from continuing operations | $137.7 million | $101.9 million | $326.4 million | $284.8 million |
| Net income | $137.1 million | $101.9 million | $325.2 million | $284.6 million |
| Diluted EPS | $2.90 | $2.16 | $6.88 | $6.01 |
| Interest expense | $23.2 million | $13.4 million | $59.3 million | $35.2 million |
Q3 revenue grew 8.7%; nine-month revenue grew 8.2%. Management attributed growth mainly to new products and price increases. Nine-month new-product sales increased $142.0 million, while existing-product volume declined $31.4 million, largely reflecting conversion to a next-generation product. Gross-margin gains reflected pricing, cost initiatives and lower logistics costs, partly offset by inflation, foreign exchange and, year to date, manufacturing productivity and recall/quality costs.
For the nine months, revenue increased across all reported segments: Americas 5.8%, EMEA 5.7%, Asia 13.5% and OEM 22.4%. Product-category growth was particularly notable in interventional (up to $375.8 million from $319.9 million), surgical ($317.8 million from $282.5 million) and OEM ($243.4 million from $198.9 million).
Cash flow, liquidity and debt
- Nine-month operating cash flow from continuing operations was $372.4 million, up from $244.4 million. The filing cites stronger operating results, lower tax payments and favorable working-capital changes, including lower inventory purchases.
- Investing cash outflow was $57.7 million, including $63.8 million of capital expenditures. Financing cash inflow was $276.0 million, including net borrowing proceeds; dividends paid were $47.9 million.
- Cash and cash equivalents were $881.5 million at October 1, 2023, compared with $292.0 million at December 31, 2022. Total borrowings, net of issuance costs, were $2,037.6 million (including $87.5 million current); cash less borrowings implies net debt of approximately $1,156.1 million.
- Borrowings increased primarily with a $600 million revolving-credit-facility draw to fund the Palette acquisition completed after quarter-end. Variable-rate revolving and term debt carried a 6.67% rate at October 1. Management stated available cash, operating cash flow and revolver capacity should fund operating needs, capital spending and debt obligations for the next 12 months and foreseeable future. The company reported compliance with debt covenants.
Material developments, outlook and risks
- Palette acquisition: Completed October 10, 2023, after the reporting period, for an initial $600 million cash payment and up to $50 million of commercial milestone consideration. The purchase was funded with revolver borrowings and cash on hand.
- Restructuring: A footprint realignment initiated in September is expected to cost $11–$15 million in restructuring and related charges, with $2–$4 million in annual pretax savings once fully implemented. Savings are expected to begin in 2024; completion is expected by the end of 2027. A separate respiratory-divestiture restructuring is expected to finish by year-end 2023.
- Defined-benefit plan: The company is pursuing termination of its frozen U.S. retirement plan, subject to PBGC approval. It estimated a $45–$55 million settlement charge in Q4 2023 from lump-sum elections, with the remaining charge expected upon annuitization in 2024. The plan had approximately $200 million of pretax accumulated other comprehensive loss associated with it.
- Contingencies: The Italian medical-device payback reserve was $12.9 million; if enforced in its existing form, payments could exceed the reserve by up to $18.6 million. A Mexican customs/tax audit could result in duties, fines and surcharges that might be material, although management did not consider a loss probable or estimable and recorded no reserve. Environmental liabilities accrued were $6.6 million; the company also disclosed ordinary-course litigation and related uncertainty.
- Operating risks: The filing highlights inflation and supply-chain disruption, raw-material availability, labor and logistics costs, product demand and acceptance, pricing and competition, reimbursement and regulatory changes, foreign exchange and interest rates, acquisition integration, and execution of restructuring and expected savings. Management reported no significant change in risk factors during the quarter.
Most important facts for investors to verify
- Whether new-product growth can offset the decline in existing-product volumes, and whether the next-generation product transition stabilizes.
- Whether gross-margin improvement persists amid inflation, quality/recall costs and foreign-exchange movements.
- Post-acquisition leverage and funding needs following the $600 million Palette purchase, including milestone payments and integration performance.
- The timing and final cost of the retirement-plan settlement, and realization of restructuring savings against their charges.
- Developments in the Italian payback appeals and Mexican audit, and any resulting liability beyond recorded reserves.